Document is current

Any future updates will be listed below

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

Crossref DOI link: https://doi.org/10.1007/s10637-015-0244-4

Published Online: 2015-05-07

Published Print: 2015-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark